Violeta Serra

List of Publications by Year
in descending order

93	12,089	50276	38395
papers	citations	46 h-index	95 g-index

104	104	104	20630
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors. Cancer Discovery, 2022, 12, 356-371.	9.4	68
2	HighFGFR1â€“4mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer. Clinical Cancer Research, 2022, 28, 137-149.	7.0	12
3	Basal expression of RAD51 foci predicts olaparib response in patient-derived ovarian cancer xenografts. British Journal of Cancer, 2022, 126, 120-128.	6.4	21
4	Antiâ€tumoural activity of the Gâ€quadruplex ligand pyridostatin against BRCA1/2â€deficient tumours. EMBO Molecular Medicine, 2022, 14, e14501.	6.9	13
5	Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient Stratification. Cancer Research, 2022, 82, 1646-1657.	0.9	40
6	MYC Inhibition Halts Metastatic Breast Cancer Progression by Blocking Growth, Invasion, and Seeding. Cancer Research Communications, 2022, 2, 110-130.	1.7	10
7	GDF15 Is an Eribulin Response Biomarker also Required for Survival of DTP Breast Cancer Cells. Cancers, 2022, 14, 2562.	3.7	6
8	Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors. European Urology, 2021, 79, 200-211.	1.9	76
9	Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. Annals of Oncology, 2021, 32, 240-249.	1.2	115
10	SLFN11 informs on standard of care and novel treatments in a wide range of cancer models. British Journal of Cancer, 2021, 124, 951-962.	6.4	40
11	Conservation of copy number profiles during engraftment and passaging of patient-derived cancer xenografts. Nature Genetics, 2021, 53, 86-99.	21.4	118
12	Mechanisms of Resistance to PI3K Inhibitors in Cancer: Adaptive Responses, Drug Tolerance and Cellular Plasticity. Cancers, 2021, 13, 1538.	3.7	37
13	Landscapes of cellular phenotypic diversity in breast cancer xenografts and their impact on drug response. Nature Communications, 2021, 12, 1998.	12.8	37
14	PI3K activation promotes resistance to eribulin in HER2-negative breast cancer. British Journal of Cancer, 2021, 124, 1581-1591.	6.4	12
15	Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. Cancer Discovery, 2021, 11, 2812-2827.	9.4	78
16	Synergistic targeting of BRCA1 mutated breast cancers with PARP and CDK2 inhibition. Npj Breast Cancer, 2021, 7, 111.	5.2	9
17	Association of RAD51 with homologous recombination deficiency (HRD) and clinical outcomes in untreated triple-negative breast cancer (TNBC): analysis of the GeparSixto randomized clinical trial. Annals of Oncology, 2021, 32, 1590-1596.	1.2	55
18	Clinical consequences of BRCA2 hypomorphism. Npj Breast Cancer, 2021, 7, 117.	5.2	3

#	Article	IF	Citations
19	Homologous Recombination Repair Deficiency and the Immune Response in Breast Cancer: A Literature Review. Translational Oncology, 2020, 13, 410-422.	3.7	52
20	ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer. Annals of Oncology, 2020, 31, 1606-1622.	1.2	238
21	Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer. Breast Cancer Research, 2020, 22, 120.	5.0	60
22	Personalized cancer therapy prioritization based on driver alteration co-occurrence patterns. Genome Medicine, 2020, 12, 78.	8.2	10
23	Tumors defective in homologous recombination rely on oxidative metabolism: relevance to treatments with <scp>PARP</scp> inhibitors. EMBO Molecular Medicine, 2020, 12, e11217.	6.9	37
24	Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts. Clinical Cancer Research, 2020, 26, 3720-3731.	7.0	21
25	The Altered Transcriptome and DNA Methylation Profiles of Docetaxel Resistance in Breast Cancer PDX Models. Molecular Cancer Research, 2019, 17, 2063-2076.	3.4	20
26	Chromosome 12p Amplification in Triple-Negative/BRCA1-Mutated Breast Cancer Associates with Emergence of Docetaxel Resistance and Carboplatin Sensitivity. Cancer Research, 2019, 79, 4258-4270.	0.9	17
27	A decade of clinical development of PARP inhibitors in perspective. Annals of Oncology, 2019, 30, 1437-1447.	1.2	437
28	Controversies in oncology: are genomic tests quantifying homologous recombination repair deficiency (HRD) useful for treatment decision making?. ESMO Open, 2019, 4, e000480.	4.5	47
29	Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy. Journal of Clinical Oncology, 2019, 37, 2257-2269.	1.6	135
30	Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs. Molecular Cancer Therapeutics, 2019, 18, 771-779.	4.1	27
31	BRCA1 intronic Alu elements drive gene rearrangements and PARP inhibitor resistance. Nature Communications, 2019, 10, 5661.	12.8	45
32	Coamplification of miR-4728 protects HER2 -amplified breast cancers from targeted therapy. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E2594-E2603.	7.1	23
33	Activity of HSP90 Inhibiton in a Metastatic Lung Cancer Patient With a Germline BRCA1 Mutation. Journal of the National Cancer Institute, 2018, 110, 914-917.	6.3	16
34	RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer. Annals of Oncology, 2018, 29, 1203-1210.	1.2	280
35	MSK1 regulates luminal cell differentiation and metastatic dormancy in ER+ breast cancer. Nature Cell Biology, 2018, 20, 211-221.	10.3	98
36	Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy. Journal of Clinical Oncology, 2018, 36, 3134-3143.	1.6	43

#	Article	IF	Citations
37	Identifying the oncogenic role of USP10 as the regulator of PTEN function in breast cancer. Annals of Oncology, 2018, 29, iii10-iii11.	1.2	2
38	356Effect of renin-angiotensin system blockade in long term outcomes following transcatheter aortic valve implantation. European Heart Journal, 2018, 39, .	2.2	0
39	p95HER2â€“T cell bispecific antibody for breast cancer treatment. Science Translational Medicine, 2018, 10, .	12.4	59
40	A <scp>RAD</scp> 51 assay feasible in routine tumor samples calls <scp>PARP</scp> inhibitor response beyond <scp>BRCA</scp> mutation. EMBO Molecular Medicine, 2018, 10, .	6.9	169
41	In vivo phosphoproteomics reveals kinase activity profiles that predict treatment outcome in triple-negative breast cancer. Nature Communications, 2018, 9, 3501.	12.8	45
42	Targeting p38Î± Increases DNA Damage, Chromosome Instability, and the Anti-tumoral Response to Taxanes in Breast Cancer Cells. Cancer Cell, 2018, 33, 1094-1110.e8.	16.8	70
43	Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nature Cell Biology, 2018, 20, 954-965.	10.3	291
44	Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies. Journal of Experimental Medicine, 2018, 215, 1913-1928.	8.5	41
45	TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrence. Journal of Clinical Investigation, 2018, 128, 3887-3905.	8.2	79
46	Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature Reviews Cancer, 2017, 17, 254-268.	28.4	527
47	Resistance to Taxanes in Triple-Negative Breast Cancer Associates with the Dynamics of a CD49f+ Tumor-Initiating Population. Stem Cell Reports, 2017, 8, 1392-1407.	4.8	62
48	Targeting the fibroblast growth factor receptor 2 in gastric cancer: promise or pitfall?. Annals of Oncology, 2017, 28, 1207-1216.	1.2	31
49	Sensitizing HR-proficient cancers to PARP inhibitors. Molecular and Cellular Oncology, 2017, 4, e1299272.	0.7	4
50	Modulation of telomere protection by the PI3K/AKT pathway. Nature Communications, 2017, 8, 1278.	12.8	47
51	mTORC1-dependent AMD1 regulation sustains polyamine metabolism in prostate cancer. Nature, 2017, 547, 109-113.	27.8	142
52	P6346Transcatheter aortic valve replacement in patients with previous mitral prostheses. European Heart Journal, 2017, 38, .	2.2	0
53	FGFR 360Â° resistance: Establishing a translational research framework in FGFR-altered (FGFRalt) patients (pt) treated with fibroblast growth factor receptor inhibitors (FGFRinh). Annals of Oncology, 2017, 28, v575.	1.2	1
54	Stratification and therapeutic potential of PML in metastatic breast cancer. Nature Communications, 2016, 7, 12595.	12.8	45

#	Article	IF	Citations
55	Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptorâ€“Positive Breast Cancer. Cancer Research, 2016, 76, 2301-2313.	0.9	509
56	The BRCA1-Î”11q Alternative Splice Isoform Bypasses Germline Mutations and Promotes Therapeutic Resistance to PARP Inhibition and Cisplatin. Cancer Research, 2016, 76, 2778-2790.	0.9	208
57	Cancer network activity associated with therapeutic response and synergism. Genome Medicine, 2016, 8, 88.	8.2	7
58	CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Reports, 2016, 17, 2367-2381.	6.4	215
59	A Biobank of Breast Cancer Explants with Preserved Intra-tumor Heterogeneity to Screen Anticancer Compounds. Cell, 2016, 167, 260-274.e22.	28.9	376
60	PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer. Nature Medicine, 2016, 22, 1303-1313.	30.7	188
61	mTOR Inhibition Beyond Rapalogs. , 2016, , 251-275.		1
62	BRCA1185delAG tumors may acquire therapy resistance through expression of RING-less BRCA1. Journal of Clinical Investigation, 2016, 126, 2903-2918.	8.2	105
63	Gain- and Loss-of-Function Mutations in the Breast Cancer Gene GATA3 Result in Differential Drug Sensitivity. PLoS Genetics, 2016, 12, e1006279.	3.5	43
64	High HER2 Expression Correlates with Response to the Combination of Lapatinib and Trastuzumab. Clinical Cancer Research, 2015, 21, 569-576.	7.0	71
65	Targeting a cell state common to tripleâ€negative breast cancers. Molecular Systems Biology, 2015, 11, 789.	7.2	21
66	Methodological aspects of the molecular and histological study of prostate cancer: Focus on PTEN. Methods, 2015, 77-78, 25-30.	3.8	16
67	PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptorâ€“positive breast cancer. Science Translational Medicine, 2015, 7, 283ra51.	12.4	276
68	MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted byTP53Mutation in Preclinical Models of Colorectal Cancer. Clinical Cancer Research, 2015, 21, 5499-5510.	7.0	18
69	Effect of p95HER2/611CTF on the Response to Trastuzumab and Chemotherapy. Journal of the National Cancer Institute, 2014, 106, .	6.3	36
70	Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors. Molecular Cancer Therapeutics, 2014, 13, 1021-1031.	4.1	375
71	mTORC1 Inhibition Is Required for Sensitivity to PI3K p110Î± Inhibitors in PIK3CA -Mutant Breast Cancer. Science Translational Medicine, 2013, 5, 196ra99.	12.4	251
72	Evaluation and Clinical Analyses of Downstream Targets of the Akt Inhibitor GDC-0068. Clinical Cancer Research, 2013, 19, 6976-6986.	7.0	72

#	Article	IF	Citations
73	Development of PI3K inhibitors: lessons learned from early clinical trials. Nature Reviews Clinical Oncology, 2013, 10, 143-153.	27.6	694
74	Clinical Response to a Lapatinib-Based Therapy for a Li-Fraumeni Syndrome Patient with a Novel HER2V659E Mutation. Cancer Discovery, 2013, 3, 1238-1244.	9.4	43
75	RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer. Journal of Clinical Investigation, 2013, 123, 2551-2563.	8.2	108
76	Dual mTORC1/2 and HER2 Blockade Results in Antitumor Activity in Preclinical Models of Breast Cancer Resistant to Anti-HER2 Therapy. Clinical Cancer Research, 2012, 18, 2603-2612.	7.0	154
77	PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition. Cancer Discovery, 2012, 2, 1036-1047.	9.4	507
78	PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene, 2011, 30, 2547-2557.	5.9	471
79	AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity. Cancer Cell, 2011, 19, 58-71.	16.8	867
80	Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast Cancer. Molecular Cancer Therapeutics, 2011, 10, 817-824.	4.1	50
81	Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2 ⁺ breast cancer patients. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 3761-3766.	7.1	291
82	NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations. Cancer Research, 2008, 68, 8022-8030.	0.9	726
83	Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235. Cancer Research, 2008, 68, 9221-9230.	0.9	474
84	Functional transcriptomics: An experimental basis for understanding the systems biology for cancer cells. Advances in Enzyme Regulation, 2007, 47, 41-62.	2.6	0
85	Analysis of gene expression profiles in melanoma cells with acquired resistance against antineoplastic drugs. Melanoma Research, 2006, 16, 147-155.	1.2	13
86	The PI3K inhibitor LY294002 blocks drug export from resistant colon carcinoma cells overexpressing MRP1. Oncogene, 2006, 25, 1743-1752.	5.9	102
87	Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene, 2005, 24, 7542-7551.	5.9	69
88	Telomere shortening in human fibroblasts is not dependent on the size of the telomeric-3'-overhang. Aging Cell, 2004, 3, 103-109.	6.7	36
89	Extracellular Superoxide Dismutase Is a Major Antioxidant in Human Fibroblasts and Slows Telomere Shortening. Journal of Biological Chemistry, 2003, 278, 6824-6830.	3.4	229
90	Human fibroblasts in vitro senesce with a donor-specific telomere length. FEBS Letters, 2002, 516, 71-74.	2.8	24

#	ARTICLE	IF	CITATIONS
91	Accelerated telomere shortening in Fanconi anemia fibroblasts - a longitudinal study. FEBS Letters, 2001, 506, 22-26.	2.8	51
92	Short Telomeres in Patients with Vascular Dementia: An Indicator of Low Antioxidative Capacity and a Possible Risk Factor?. Laboratory Investigation, 2000, 80, 1739-1747.	3.7	290
93	Telomere Length As a Marker of Oxidative Stress in Primary Human Fibroblast Cultures. Annals of the New York Academy of Sciences, 2000, 908, 327-330.	3.8	87